Delivers like nothing else.
BOLD CLINICAL TRIALS
Two Randomized Controlled DCB Trials.
Exceptional outcomes at 2-Years. No matter the lesion complexity. No matter the patient.5
In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency
2.Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
3. COMPARE Clinical Trial 2-Year Results presented by Sabine Steiner, MD. LINC 2021. Based on total drug dose for (4mmx60mm) or (average for full size matrix) per Ranger™ Paclitaxel-Coated PTA Balloon Catheter and IN.PACT™ Admiral Instructions for Use.
4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.
5. RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD. VIVA 2021.
RESTENOSIS REPLACEMENT PROGRAM
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.